Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. develops and commercializes medicines for rare diseases, with recurring updates centered on product sales, clinical readouts, regulatory interactions and employee equity grants. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis.
News about MIRM also covers clinical-stage programs including volixibat, an IBAT inhibitor for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a monoclonal antibody designed to bind hepatitis B surface antigen for chronic hepatitis delta virus; and MRM-3379, a PDE4D inhibitor for Fragile X syndrome. Company updates report financial results, pipeline licensing activity and inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq: MIRM) reported inducement grants on March 11, 2026 under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted non-qualified stock options to purchase 5,400 shares and 6,800 RSUs to five new employees.
Options carry an exercise price of $91.75 (Mirum closing price on March 11, 2026). Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years (33% each anniversary). Awards are governed by Mirum’s 2020 Inducement Plan and award agreements, and are conditioned on continued service.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported completion of enrollment in Phase 3 AZURE-1 and completion of screening in Phase 3 AZURE-4 for brelovitug in chronic hepatitis delta virus (HDV).
Topline 24-week results from both studies are expected in 2H 2026; AZURE-1 and AZURE-4 will form the basis of a U.S. BLA filing with a potential U.S. launch in 2027. Brelovitug holds Breakthrough Therapy designation from the FDA.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported 2025 net product sales of $521.3M and provided 2026 guidance of $630M–$650M in expected global net product sales. The company highlighted multiple near‑term registrational readouts in 2026 and recent regulatory approvals and an acquisition expanding its HDV program.
Key near‑term catalysts include VISTAS topline in PSC (Q2 2026), LIVMARLI EXPAND topline (Q4 2026), and AZURE HDV readouts in H2 2026. Cash and investments were $391.4M at year‑end 2025.
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in multiple investor conferences in early March 2026, including TD Cowen (March 2), Citizens Life Sciences (March 10), Barclays Global Healthcare (March 10), and Leerink Partners (March 11).
Fireside chat times: March 2 at 1:10 p.m. ET, March 10 at 10:10 a.m. ET, and March 11 at 10:00 a.m. ET. The company said the sessions will be webcast live and available for replay in Mirum's Investors section.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report fourth quarter and year‑end 2025 financial results on February 25, 2026. A conference call and webcast will follow to discuss results and recent corporate progress.
The live call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT; dial‑in and webcast replay details are provided for investors.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards granted on February 10, 2026 to 37 new employees under its 2020 Inducement Plan. Awards include 163,040 non-qualified stock options at an exercise price of $100.91, 219,090 RSUs, and 48,880 PSUs.
Options vest over four years, RSUs vest over three years, and PSUs vest March 15, 2028 and March 15, 2029 if specified net product sales targets for 2027 and 2028 are met and service conditions are satisfied.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced Health Canada authorization of the LIVMARLI tablet formulation for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) who weigh 22 kg or more and can swallow tablets.
The tablet complements the existing 9.5 mg/mL oral solution previously authorized for patients aged 12 months and older, offering an additional dosing option to support adherence and continuity of care. Mirum also announced Health Canada authorization for LIVMARLI in progressive familial intrahepatic cholestasis (PFIC) earlier the same day, covering both 19 mg/mL solution and tablet formulations.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced Health Canada authorization of LIVMARLI (maralixibat) for treatment of cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC).
Authorization covers a 19 mg/mL oral solution and a tablet formulation (for patients ≥22 kg) and is supported by Phase 3 MARCH data (93 patients; p<0.0001 versus placebo).
Mirum Pharmaceuticals (NASDAQ: MIRM) completed its acquisition of Bluejay Therapeutics, acquiring worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV).
Brelovitug holds FDA Breakthrough Therapy and EMA PRIME designations and is in the global AZURE Phase 3 registrational program with topline data expected in 2H 2026. Mirum financed the deal via cash and stock consideration plus potential tiered sales‑based milestones and closed concurrent private placement financings raising approximately $268.5 million to support clinical development and commercial activities.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants made on January 9, 2026 to five new employees under its 2020 Inducement Plan. The Compensation Committee granted non-qualified stock options to purchase 4,900 shares and 6,500 restricted stock units (RSUs).
Each option has an exercise price of $86.57 per share (Mirum's closing price on January 9, 2026). Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years (33% on each anniversary). Grants are subject to the 2020 Inducement Plan and applicable award agreements and to continued service through vesting dates.